1910 Genetics
PrivateLast Round
Series A
Extension
Oct 31, 2024
Total Funding Raised
$40.55M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
1910 Genetics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A Extension round in October 2024.
1910 Genetics is a biotechnology company that provides a drug discovery platform utilizing multimodal AI and laboratory automation to enhance productivity and reduce failure rates in small and large molecule drug development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS, Government Contracts
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
1910 Genetics Comparables
Compare 1910 Genetics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Terray Therapeutics | 84% | |
| Iambic Therapeutics | 84% | |
| PostEra | 84% |
For institutional investors. Book with your work email.
1910 Genetics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 31, 2024 | ||||
| Grant | Sep 30, 2021 | ||||
| Series A | Mar 23, 2021 |
For institutional investors. Book with your work email.
1910 Genetics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Scientia Ventures | Seed, Series A |
| Emles | Seed, Series A |
| NIH Helping to End Addiction Long-term (HEAL) Initiative | Grant |
| NIH RADx | Grant |
| FoundersX Ventures | Seed |
| Playground Global | Series A |
| M12 - Microsoft's Venture Fund | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 84% MoM.
- Oct 31, 2024
$14M round led by Accenture Ventures
For institutional investors. Book with your work email.
1910 Genetics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about 1910 Genetics's valuation, stock price, and market status.
Is 1910 Genetics a public or private company?
1910 Genetics is a private company.
What is the current stock price of 1910 Genetics?
1910 Genetics is a private company, so its shares have no public market price. Caplight tracks 1910 Genetics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is 1910 Genetics worth (valuation)?
Valuation information for 1910 Genetics is not publicly available.
Can I buy 1910 Genetics stock?
1910 Genetics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was 1910 Genetics's last funding round?
1910 Genetics's most recent funding round was Series A Extension on October 31, 2024.
Who are the main investors in 1910 Genetics?
Key investors in 1910 Genetics include NIH RADx, Playground Global, M12 - Microsoft's Venture Fund, Accenture Ventures, Playground Global.
Will 1910 Genetics IPO soon?
No public IPO plans have been announced for 1910 Genetics.
How can I track 1910 Genetics secondary market activity?
Caplight tracks bids, offers, and trades in 1910 Genetics's shares on secondary markets.